Technical Analysis for ATHX - Athersys, Inc.

Grade Last Price % Change Price Change
F 1.75 1.16% 0.02
ATHX closed up 5.49 percent on Wednesday, April 21, 2021, on 77 percent of normal volume.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical ATHX trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 1.16%
Hammer Candlestick Bullish 6.71%
NR7 Range Contraction 6.71%
MACD Bearish Signal Line Cross Bearish 7.36%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.55%
Outside Day Range Expansion 3.55%
NR7 Range Contraction 1.74%
Inside Day Range Contraction 1.74%
Down 3 Days in a Row Weakness 3.86%
Down 4 Days in a Row Weakness 3.86%
Older End-of-Day Signals for ATHX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 4 hours ago
Up 2% about 5 hours ago
20 DMA Resistance about 5 hours ago
Rose Above 20 DMA about 6 hours ago
60 Minute Opening Range Breakout about 6 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Athersys, Inc. Description

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diseases Clinical Development Pharmaceuticals Diabetes Pharmacy Bone Drug Discovery Clinical Trial Schizophrenia Cardiovascular Disease Inflammatory Bowel Disease Obesity Regenerative Medicine Immune Disorders Cell Product Mesoblast Orthopedic Applications Platform Product

Is ATHX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.39
52 Week Low 1.53
Average Volume 2,746,215
200-Day Moving Average 2.07
50-Day Moving Average 1.98
20-Day Moving Average 1.75
10-Day Moving Average 1.73
Average True Range 0.12
ADX 22.04
+DI 17.37
-DI 22.64
Chandelier Exit (Long, 3 ATRs ) 1.62
Chandelier Exit (Short, 3 ATRs ) 1.92
Upper Bollinger Band 1.95
Lower Bollinger Band 1.55
Percent B (%b) 0.46
BandWidth 22.91
MACD Line -0.07
MACD Signal Line -0.07
MACD Histogram 0.001
Fundamentals Value
Market Cap 342.02 Million
Num Shares 198 Million
EPS -0.31
Price-to-Earnings (P/E) Ratio -5.65
Price-to-Sales 667.12
Price-to-Book 7.70
PEG Ratio -0.34
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.91
Resistance 3 (R3) 1.89 1.82 1.88
Resistance 2 (R2) 1.82 1.77 1.83 1.87
Resistance 1 (R1) 1.77 1.74 1.80 1.79 1.86
Pivot Point 1.70 1.70 1.71 1.71 1.70
Support 1 (S1) 1.65 1.65 1.68 1.67 1.60
Support 2 (S2) 1.58 1.62 1.59 1.59
Support 3 (S3) 1.53 1.58 1.58
Support 4 (S4) 1.55